The use of classification and regression trees to predict the likelihood of seasonal influenza by Afonso, Anna M. et al.
© The Author 2012. Published by Oxford University Press. All rights reserved. 
For permissions, please e-mail: journals.permissions@oup.com.
 The Author 2012. Published by f r i r it .Family Practice 2012; 00:1–7
doi:10.1093/fampra/cms020
Theuseof classificationand regression trees topredict
the likelihood of seasonal influenza
Anna M Afonsoa, Mark H Ebella,*, Ralph Gonzalesb, John Steinc,
Blaise Gentond and Nicolas Senne
aDepartment of Epidemiology and Biostatistics, University of Georgia, Athens, Georgia, USA, bDepartment of Internal Medicine
and cDepartment of EmergencyMedicine, University of California, San Francisco, CA, USA, dInfectious Disease Service, Department
of Ambulatory Care and Community Medicine, University Hospital, Lausanne, Switzerland and eDepartment of Ambulatory Care
and Community Medicine, University of Lausanne, Lausanne, Switzerland.
*Correspondence to Mark H Ebell, Department of Epidemiology and Biostatistics, University of Georgia, N129A Coverdell Building,
Athens, GA 30602, USA; E-mail: ebell@uga.edu
Received 9 October 2011; Revised 5 February 2012; Accepted 6 February 2012.
Background. Individual signs and symptoms are of limited value for the diagnosis of influenza.
Objective. To develop a decision tree for the diagnosis of influenza based on a classification and
regression tree (CART) analysis.
Methods. Data from two previous similar cohort studies were assembled into a single dataset.
The data were randomly divided into a development set (70%) and a validation set (30%). We
used CART analysis to develop three models that maximize the number of patients who do not
require diagnostic testing prior to treatment decisions. The validation set was used to evaluate
overfitting of the model to the training set.
Results. Model 1 has seven terminal nodes based on temperature, the onset of symptoms and
the presence of chills, cough and myalgia. Model 2 was a simpler tree with only two splits based
on temperature and the presence of chills. Model 3 was developed with temperature as a dichot-
omous variable (>38C) and had only two splits based on the presence of fever andmyalgia. The
area under the receiver operating characteristic curves (AUROCC) for the development and val-
idation sets, respectively, were 0.82 and 0.80 for Model 1, 0.75 and 0.76 for Model 2 and 0.76 and
0.77 for Model 3. Model 2 classified 67% of patients in the validation group into a high- or low-
risk group compared with only 38% for Model 1 and 54% for Model 3.
Conclusions. A simple decision tree (Model 2) classified two-thirds of patients as low or high risk
and had an AUROCC of 0.76. After further validation in an independent population, this CART
model could support clinical decision making regarding influenza, with low-risk patients requir-
ing no further evaluation for influenza and high-risk patients being candidates for empiric symp-
tomatic or drug therapy.
Keywords. Clinical decision rules, common illnesses, infectious disease, influenza, primary
care, public health, respiratory infections.
Introduction
In a typical year, 5% to 20% of the population is
affected by seasonal influenza.1 The public health
impact includes a loss in workforce productivity,
200 000 hospitalizations each year and up to 49 000
flu-related deaths per year in the USA alone.1 While
vaccination is the cornerstone of influenza prevention,
the vaccine has incomplete uptake and limited
effectiveness.2
A timely diagnosis of influenza has the potential to
improve the allocation of medical resources, prevent
the inappropriate use of antibiotics and permit the
prompt initiation of antiviral therapy if patients are di-
agnosed within 36 hours of symptom onset.3 The latter
has been demonstrated to reduce the duration of
symptoms by 24 hours.2
Patients with seasonal influenza typically present
with fever, chills, cough, myalgias, sore throat, head-
ache and fatigue.4 Because other respiratory infections
may have a similar clinical presentation,5 information
from individual signs and symptoms is of limited value
for diagnosing influenza. Clinical decision rule that in-
tegrates several signs and symptoms could be used in
conjunction with information about the baseline prev-
alence of influenza in the community to classify
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patients as low risk (below the test threshold, requir-
ing no further evaluation), above the treatment
threshold (candidates for empiric therapy) or between
the test and treatment threshold (candidates for fur-
ther testing).6 While previous studies7–13 have identi-
fied simple heuristics to identify patients with
influenza (i.e. a ‘fever and cough’ rule), their accuracy
is variable and limited, with a sensitivity and specificity
ranging from 30% to 80% and 55% to 95%14, respec-
tively. Previous attempts to create multivariate models
have been limited by poor reporting or failure to vali-
date the resulting models using either a ‘split sample’
approach or a new population.10,15 In a recent study,
we developed and validated a clinical decision rule
based on a logistic regression model that was able to
classify 50% of subjects as being high risk or low
risk.16
Classification and regression trees (CARTs)17 are
an alternative to logistic regression for the creation of
clinical decision rules. This approach has the advan-
tage of not making any assumptions about the under-
lying statistical model (i.e. it is a model-free
estimator) and the resulting decision trees have good
face validity and are easily applied at the bedside.
The aim of this investigation is to use CART analysis
to develop and internally validate a clinical decision
rule to stratify the risk of influenza using the history
and physical examination.
Methods
Dataset
We identified two studies, one from California and
one from Switzerland, that evaluated the accuracy of
the history and physical examination in consecutive
adults with suspected influenza or acute respiratory
tract infection in the outpatient setting during flu
season. Characteristics of the combined dataset are re-
ported in Table 1.7,18 Because the study populations
were so similar, we chose to combine the datasets in
order to be able to create a development set with
70% of the data (n = 322) and a separate validation
set with 30% of the data (n = 137). This assured an ad-
equate number of patients for model development and
increased generalizability. Simply using one commun-
ity’s data for the development set would not have re-
sulted in enough cases in that group to reliably create
a CART model. The final prevalence of influenza is
typical of that during peak flu season in US surveil-
lance studies. Thus, rather than using two independent
populations for the development and validation sets,
each set was randomly selected from the combined da-
taset. The validation set was not used during model
development; it was reserved to perform the final vali-
dation of the candidate models.
Variables that were considered to have nearly the
same clinical meaning were combined under a single
variable (i.e. ‘rhinitis’ and ‘runny nose’, ‘myalgia’ and
‘muscle pain’ and ‘chills and sweating’ and ‘sweats’).
Acute onset was defined as the presentation of symp-
toms to a physician within 48 hours of symptom onset.
Variables reported in one study but not another were
eliminated from the combined dataset.
The prevalence of influenza for the study conducted
in a primary care clinic (53%) was higher than the
prevalence of influenza in the study conducted in an
urgent care setting (20%), yielding a prevalence of
33% in the final dataset. The latter pretest probability
is typical of the peak of influenza season in the USA,
which ranged from 25% to 40% in 2010–11, 25% to
45% in 2009–10 and 20% to 30% in 2008–09.19 These
are rough generalizations based on the Centers for
Disease Control and Prevention’s weekly surveillance
data and do not represent the total prevalence of
influenza A and B, but the proportion of influenza
TABLE 1 Characteristics of included studies
Swiss population18 US population
Number of patients 201 258
Setting University primary care clinic that serves an
urban population of 150 000 in Lausanne,
Switzerland
Emergency Department or urgent care
ambulatory patients in a large tertiary care
University Hospital in San Francisco, CA
Date December 1999 to February 2000 January 2002 to March 2002
Inclusion criteria Adult outpatients with influenza-like illness as
determined by the primary care physician
Consecutive adults with symptoms of an acute
respiratory tract infection (cough, sinus pain,
congestion/rhinorrohea, sore throat or fever
developing in past 3 weeks)
Mean age (range) 34.3 (17–86) 38.8 (18–90)
Prevalence of influenza (%) 104/201 (52.8) 53/258 (20.5)
Reference standard Culture Polymerase chain reaction
Independent predictors of influenza odds ratio
(95% confidence interval)
Fever; 4.24 (2.33–7.71) Myalgia; 4.22 (1.96–9.1)
Myalgia; 2.76 (1.01–7.49) Fever; 3.84 (1.98–7.45)
Chills; 3.37 (1.6–7.06)
Rhinitis; 2.22 (1.02–4.82)
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diagnoses out of the total outpatient visits for influ-
enza-like illness (ILI). It is possible that the higher
prevalence in the Swiss study could be due to differing
selection criteria that identified patients more likely to
have the flu. Culture was the reference standard test in
the Swiss study, while polymerase chain reaction was
the reference standard test in the American study.
Software
The univariate analysis was performed with Stata ver-
sion 11.0 (College Station, TX). The creation of
a CART was performed with JMP 8.0.2 (SAS
Institute).
CART analysis
Unlike logistic regression, CART analysis does not re-
quire postulation of an underlying model.20 Therefore,
CART is able to discover complex interactions
between variables, an advantage for data in which the
relationships between predictors and outcome is un-
clear. It is a non-parametric technique, not requiring
assumptions about the distribution of data.
In our analysis, the outcome variable was binary:
identification of flu by the reference standard. All
symptoms recorded in both studies were included in
the determination of the model (excluding gender and
age), regardless of whether they were significant pre-
dictors of flu (Table 3). Gender (P = 0.60) and age
were omitted from the analysis because they did not
show clinical or statistical significance. The only varia-
bles that were included in the model but were not sig-
nificant predictors of flu were headache (P = 0.05)
and sore throat (P = 0.75). Temperature was the only
continuous predictor, while binary predictor variables
included the presence of myalgia, cough, rhinitis, sore
throat, headache, fatigue, chills/sweating, acute onset
of symptoms and fever. In Models 1 and 2, tempera-
ture was a continuous variable. In Model 3, tempera-
ture was dichotomized at a temperature of 38C to
create a binary fever variable.
CART involves binary recursive partitioning, which
splits a single parent node into two daughter nodes
based on the predictor variable that best stratifies the
population into groups with and without the outcome
of interest. Each daughter node can be split further into
two nodes and so on. The partition algorithm obtains
all possible splits and calculates a likelihood ratio (LR)
chi-square statistic for a test of independence for each
possible split. The P value for the chi-square test repre-
sents the probability of getting a chi-square value
greater than the one found by chance alone. The crite-
rion used for selecting splits of the nodes was set to
‘maximize significance’. This means that splits were
chosen based on significance values for each split candi-
date rather than the raw test statistic. Each candidate
variable is ranked by its logworth statistic to identify
the optimal split for each node (the logworth statistic is
the negative log of adjusted P values for the chi-square
statistic).21
For continuous variables, splits are constructed
around a cutting value that maximizes the separation
of the groups.22 The separation of groups is measured
by the sum of squares for the differences between the
means of the two groups.20 Missing values were as-
signed to ‘closes which assigns the missing value based
on patterns identified from the non-missing data.21
There were only 11 cases in the derivation set that
were missing a value for temperature and 3 in the vali-
dation set missing temperature.
In this analysis, the minimum split size was set to
JMP’s default setting: five patients in a single group
(1% of the total sample). We set a fairly low minimum
split size in order to be able to grow out and then
manually prune the tree back. We ‘manually’ pruned
the tree by examining how many additional patients
could be classified as high or low risk, which we con-
sidered the most desirable groups for classification
since they would not require further diagnostic testing
according to the test and treatment thresholds defined
below. Other goals for our CART models were that
they maintain good face validity for patients and clini-
cians and that they are simple to use.
Models 1 and 3 were built by first growing out the
tree by manually splitting according to the optimal
logworth statistic. We then manually pruned back the
tree, omitting variables that did not further classify
a substantial percentage of patients into a high- or
low-risk group. Model 2 is a reduced version of Model
1. Another method used to develop CART models in-
volved automatic repeated splitting according to the
logworth statistic until the R-square was better than
what the next 10 splits would obtain.21 Automatic
splitting obtained the same result as Model 1 except
that myalgia and temperature >37.85C are omitted
from the model. Automatic splitting obtained the
same result for Model 3. Results for the manually
modified trees are shown in Tables 3 and 4.
Test and treatment thresholds
In a previous study,16 we surveyed a group of 20 gen-
eralist physicians about their testing and treatment
preferences regarding influenza. Based on these data,
we established a test threshold of 10%, below which
neither testing nor treatment was indicated, and
a treatment threshold of 50%, above which empiric
antiviral therapy should be considered. These thresh-
olds are also consistent with those reported in a previ-
ous decision threshold analysis.23
Analysis
As noted earlier, 30% of the dataset was not included
in this analysis as it was reserved for validation. These
data were not used during model development. We
calculated receiver operating characteristic curves to
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patients as low risk (below the test threshold, requir-
ing no further evaluation), above the treatment
threshold (candidates for empiric therapy) or between
the test and treatment threshold (candidates for fur-
ther testing).6 While previous studies7–13 have identi-
fied simple heuristics to identify patients with
influenza (i.e. a ‘fever and cough’ rule), their accuracy
is variable and limited, with a sensitivity and specificity
ranging from 30% to 80% and 55% to 95%14, respec-
tively. Previous attempts to create multivariate models
have been limited by poor reporting or failure to vali-
date the resulting models using either a ‘split sample’
approach or a new population.10,15 In a recent study,
we developed and validated a clinical decision rule
based on a logistic regression model that was able to
classify 50% of subjects as being high risk or low
risk.16
Classification and regression trees (CARTs)17 are
an alternative to logistic regression for the creation of
clinical decision rules. This approach has the advan-
tage of not making any assumptions about the under-
lying statistical model (i.e. it is a model-free
estimator) and the resulting decision trees have good
face validity and are easily applied at the bedside.
The aim of this investigation is to use CART analysis
to develop and internally validate a clinical decision
rule to stratify the risk of influenza using the history
and physical examination.
Methods
Dataset
We identified two studies, one from California and
one from Switzerland, that evaluated the accuracy of
the history and physical examination in consecutive
adults with suspected influenza or acute respiratory
tract infection in the outpatient setting during flu
season. Characteristics of the combined dataset are re-
ported in Table 1.7,18 Because the study populations
were so similar, we chose to combine the datasets in
order to be able to create a development set with
70% of the data (n = 322) and a separate validation
set with 30% of the data (n = 137). This assured an ad-
equate number of patients for model development and
increased generalizability. Simply using one commun-
ity’s data for the development set would not have re-
sulted in enough cases in that group to reliably create
a CART model. The final prevalence of influenza is
typical of that during peak flu season in US surveil-
lance studies. Thus, rather than using two independent
populations for the development and validation sets,
each set was randomly selected from the combined da-
taset. The validation set was not used during model
development; it was reserved to perform the final vali-
dation of the candidate models.
Variables that were considered to have nearly the
same clinical meaning were combined under a single
variable (i.e. ‘rhinitis’ and ‘runny nose’, ‘myalgia’ and
‘muscle pain’ and ‘chills and sweating’ and ‘sweats’).
Acute onset was defined as the presentation of symp-
toms to a physician within 48 hours of symptom onset.
Variables reported in one study but not another were
eliminated from the combined dataset.
The prevalence of influenza for the study conducted
in a primary care clinic (53%) was higher than the
prevalence of influenza in the study conducted in an
urgent care setting (20%), yielding a prevalence of
33% in the final dataset. The latter pretest probability
is typical of the peak of influenza season in the USA,
which ranged from 25% to 40% in 2010–11, 25% to
45% in 2009–10 and 20% to 30% in 2008–09.19 These
are rough generalizations based on the Centers for
Disease Control and Prevention’s weekly surveillance
data and do not represent the total prevalence of
influenza A and B, but the proportion of influenza
TABLE 1 Characteristics of included studies
Swiss population18 US population
Number of patients 201 258
Setting University primary care clinic that serves an
urban population of 150 000 in Lausanne,
Switzerland
Emergency Department or urgent care
ambulatory patients in a large tertiary care
University Hospital in San Francisco, CA
Date December 1999 to February 2000 January 2002 to March 2002
Inclusion criteria Adult outpatients with influenza-like illness as
determined by the primary care physician
Consecutive adults with symptoms of an acute
respiratory tract infection (cough, sinus pain,
congestion/rhinorrohea, sore throat or fever
developing in past 3 weeks)
Mean age (range) 34.3 (17–86) 38.8 (18–90)
Prevalence of influenza (%) 104/201 (52.8) 53/258 (20.5)
Reference standard Culture Polymerase chain reaction
Independent predictors of influenza odds ratio
(95% confidence interval)
Fever; 4.24 (2.33–7.71) Myalgia; 4.22 (1.96–9.1)
Myalgia; 2.76 (1.01–7.49) Fever; 3.84 (1.98–7.45)
Chills; 3.37 (1.6–7.06)
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diagnoses out of the total outpatient visits for influ-
enza-like illness (ILI). It is possible that the higher
prevalence in the Swiss study could be due to differing
selection criteria that identified patients more likely to
have the flu. Culture was the reference standard test in
the Swiss study, while polymerase chain reaction was
the reference standard test in the American study.
Software
The univariate analysis was performed with Stata ver-
sion 11.0 (College Station, TX). The creation of
a CART was performed with JMP 8.0.2 (SAS
Institute).
CART analysis
Unlike logistic regression, CART analysis does not re-
quire postulation of an underlying model.20 Therefore,
CART is able to discover complex interactions
between variables, an advantage for data in which the
relationships between predictors and outcome is un-
clear. It is a non-parametric technique, not requiring
assumptions about the distribution of data.
In our analysis, the outcome variable was binary:
identification of flu by the reference standard. All
symptoms recorded in both studies were included in
the determination of the model (excluding gender and
age), regardless of whether they were significant pre-
dictors of flu (Table 3). Gender (P = 0.60) and age
were omitted from the analysis because they did not
show clinical or statistical significance. The only varia-
bles that were included in the model but were not sig-
nificant predictors of flu were headache (P = 0.05)
and sore throat (P = 0.75). Temperature was the only
continuous predictor, while binary predictor variables
included the presence of myalgia, cough, rhinitis, sore
throat, headache, fatigue, chills/sweating, acute onset
of symptoms and fever. In Models 1 and 2, tempera-
ture was a continuous variable. In Model 3, tempera-
ture was dichotomized at a temperature of 38C to
create a binary fever variable.
CART involves binary recursive partitioning, which
splits a single parent node into two daughter nodes
based on the predictor variable that best stratifies the
population into groups with and without the outcome
of interest. Each daughter node can be split further into
two nodes and so on. The partition algorithm obtains
all possible splits and calculates a likelihood ratio (LR)
chi-square statistic for a test of independence for each
possible split. The P value for the chi-square test repre-
sents the probability of getting a chi-square value
greater than the one found by chance alone. The crite-
rion used for selecting splits of the nodes was set to
‘maximize significance’. This means that splits were
chosen based on significance values for each split candi-
date rather than the raw test statistic. Each candidate
variable is ranked by its logworth statistic to identify
the optimal split for each node (the logworth statistic is
the negative log of adjusted P values for the chi-square
statistic).21
For continuous variables, splits are constructed
around a cutting value that maximizes the separation
of the groups.22 The separation of groups is measured
by the sum of squares for the differences between the
means of the two groups.20 Missing values were as-
signed to ‘closes which assigns the missing value based
on patterns identified from the non-missing data.21
There were only 11 cases in the derivation set that
were missing a value for temperature and 3 in the vali-
dation set missing temperature.
In this analysis, the minimum split size was set to
JMP’s default setting: five patients in a single group
(1% of the total sample). We set a fairly low minimum
split size in order to be able to grow out and then
manually prune the tree back. We ‘manually’ pruned
the tree by examining how many additional patients
could be classified as high or low risk, which we con-
sidered the most desirable groups for classification
since they would not require further diagnostic testing
according to the test and treatment thresholds defined
below. Other goals for our CART models were that
they maintain good face validity for patients and clini-
cians and that they are simple to use.
Models 1 and 3 were built by first growing out the
tree by manually splitting according to the optimal
logworth statistic. We then manually pruned back the
tree, omitting variables that did not further classify
a substantial percentage of patients into a high- or
low-risk group. Model 2 is a reduced version of Model
1. Another method used to develop CART models in-
volved automatic repeated splitting according to the
logworth statistic until the R-square was better than
what the next 10 splits would obtain.21 Automatic
splitting obtained the same result as Model 1 except
that myalgia and temperature >37.85C are omitted
from the model. Automatic splitting obtained the
same result for Model 3. Results for the manually
modified trees are shown in Tables 3 and 4.
Test and treatment thresholds
In a previous study,16 we surveyed a group of 20 gen-
eralist physicians about their testing and treatment
preferences regarding influenza. Based on these data,
we established a test threshold of 10%, below which
neither testing nor treatment was indicated, and
a treatment threshold of 50%, above which empiric
antiviral therapy should be considered. These thresh-
olds are also consistent with those reported in a previ-
ous decision threshold analysis.23
Analysis
As noted earlier, 30% of the dataset was not included
in this analysis as it was reserved for validation. These
data were not used during model development. We
calculated receiver operating characteristic curves to
Page 3 of 7CART analysis to predict the risk of influenza     t  ris  of influenza 673
assess the overall diagnostic accuracy of the CART
models.24 CARTs were used to stratify patients into
low-, moderate- and high-risk groups. The post-test
probability of influenza and LR was calculated for
each of the terminal nodes in the CART tree. We used
this approach (rather than a bootstrap evaluation) be-
cause it allowed us to specify cut-offs for classification
into low-, moderate- and high-risk groups prior to
evaluation in the validation set.
Results
An analysis of patient symptoms according to influ-
enza status for the combined dataset (Table 2) shows
that patients with influenza had a much higher per-
centage of fever (63% versus 24%) and myalgia (90%
versus 63%) as well as a moderately higher percentage
of chills/sweating (85% versus 63%). However, there
is significant similarity in the prevalence of other
symptoms between cases and non-cases.
We developed three candidate CART models,
shown in Figures 1–3 (the full models are shown in
Fig. A1–A3). Model 1 (Fig. A1) initially had six splits
and seven terminal nodes but was simplified (Fig. 1)
by combining terminal nodes into a single ‘moderate-
risk’ group and by omitting ‘temperature >37.85C’
and ‘myalgia’ splits that added only 16 or 7 patients,
respectively, into high- or low-risk categories. Models
2 and 3 had only two splits and three terminal nodes.
In Models 1 and 2, temperature >37.4C (99.3 F) was
the most important predictor variable. This cut-off for
temperature was chosen by the CART algorithm as
the optimal split but may be problematic since it is at
the upper bound of the normal range. In Model 3, we
included temperature as a prespecified dichotomous
variable with a cut-off >38C (100.4 F), which is more
typical of an abnormal temperature in usual clinical
practice. Although gender and age were considered
optimal candidates for splits by the algorithm, we did
not include these splits in the model as previous multi-
variate and univariate analyses did not identify age or
gender as important variables.
Because our modelling goals were to maximize
identification of low- and high-risk patients who would
not require further diagnostic testing and to favour
simplicity, we combined the terminal nodes in Model
1 that had a probability of influenza between 10%
and 50% into a single moderate probability node.
Model 2 only had three terminal nodes, which we
designated as low, moderate and high risk. The post-
test probability and LR of flu for each node and for
the combined low-, moderate- and high-risk groups of
each model are shown in Table 3.
The most clinically useful information gained by us-
ing the prediction model is the percentage of patients
classified as low and high risk since that information
has the potential to change clinical practice. We report
separately the accuracy of Models 1, 2 and 3 for the
development, validation and combined datasets. This
percentage decreased less between derivation and val-
idation groups for Model 2 (71%–67%) than it did for
Model 1 (41%–32%) or Model 3 (57%–48%). The
key design and performance characteristics of the
TABLE 2 Symptom prevalence by influenza status
Symptom/characteristic % With
symptom
Prevalence of
symptom in influenza
positive (N = 157)
Prevalence of
symptom in influenza
negative (N = 302)
P value
Mean age (SD) 37 (14) 36 (13) 37 (15)
Temperature (C)a (SD) 37.51 (0.88) 38.03 (0.80) 37.23 (0.79)
Maleb 45 67/156 (43%) 137/301 (46%) 0.60
Fever (>37.8C)a 37 99/157 (63%) 71/302 (24%) <0.0001a
Chills 71 134/157 (85%) 190/302 (63%) <0.0001a
Myalgia 72 142/157 (90%) 193/302 (64%) <0.0001a
Duration of symptoms <2 days before
presentation
33 82/157 (52%) 69/302 (23%) <0.0001a
Fatigue 83 141/157 (90%) 240/302 (79%) 0.005a
Cough 92 150/157 (96%) 271/302 (90%) 0.03a
Rhinitis 76 128/157 (82%) 220/302 (73%) 0.04a
Headache 78 131/157 (83%) 228/302 (76%) 0.05
Sore throat 72 115/157 (73%) 217/302 (72%) 0.75
Note: The following variables that were reported in one study but not another were eliminated from the combined dataset: race, whether the visit
was the first for the given illness, days missed from work, duration of illness in days, presence of a co-morbidity, sinus pain, whether discharge was
present, colour of discharge, throat swelling, difficult swallowing, whether phlegmwas dry or scant, whether blood was present in phlegm, wheezing,
shortness of breath, painful breathing, chest pain, abdominal pain, vomiting, diarrhoea, pulse, blood pressure, respiratory rate, oxygen saturation,
toxic appearance, TM abnormality, purulent sinus drainage, sinus tenderness, tonsillar swelling, tonsillar exudates, cervical lymphadenopathy, pro-
longed expiration, decreased breath sounds, rales, rinchi, wheezes, abdominal tenderness, a clinician’s diagnosis of influenza, the results of a rapid
flu test and the week that the patient presented with symptoms.
aTemperature missing for 14 patients.
bGender missing for two patients.
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three candidate CART models are summarized in
Table 4, including the area under the receiver operat-
ing characteristic curve (AUROCC), LR’s and per-
centage of patients classified into useful risk
categories for the development and validation set for
each model.
Discussion
Model 1 has a higher AUROCC than Model 2, may
be more acceptable or believable because it uses more
clinical variables and has a higher LR for the high-risk
category. Model 2, on the other hand, is simpler and
easier to use and classifies more patients below the
test threshold or above the treatment threshold than
Model 1 (67% versus 32% for the validation set).
These are the most clinically useful classifications be-
cause they help a physician rule out or rule in influ-
enza. Model 3 has a slightly higher AUROCC than
Model 2 but classifies only 49% of validation set
patients into high- or low-risk categories. An advan-
tage of Model 3, however, is that it utilizes a tempera-
ture cut-off for fever that may be more acceptable to
physicians.
While on balance we feel that Model 2 provides the
most clinically useful model, all the models are reason-
able options depending on patient and physician prefer-
ences. Models 2 and 3 in particular could be easily
memorized. For example, during flu season, patients
with fever and an onset of symptoms <48 hours should
be empirically treated (unless there is some other obvi-
ous aetiology for their fever such as exudative pharyn-
gitis, otitis media or sinus pain and tenderness). Those
without fever but with chills or sweats should be tested
for influenza, while those without either symptom are
unlikely to have influenza. Note that this simplified
model is only an aid to clinician judgement; it is impor-
tant to remain vigilant for pneumonia and other un-
common but serious causes of similar symptoms. While
these models were accurate in our population, they
should be further validated in an independent popula-
tion that also assesses the impact on cost, test ordering,
prescribing and clinical outcomes.
CART has several advantages as a tool for develop-
ing clinical decision rules. While traditional statistical
techniques require the postulation of a model, CART
does not. When complex interactions and patterns exist
in data, they can be difficult or virtually impossible to
model.22 Furthermore, multivariate models are com-
plex, and even point scores may generate non-intuitive
results (for example when different combinations of
two or three variables give different results). A decision
tree, on the other hand, is easily understood by both
patients and physicians.
FIGURE 1 Simplified CART for Model 1 (see Fig. A1 for full
model)
FIGURE 2 CART for Model 2 (see Fig. A2 for full model)
FIGURE 3 CART for Model 3 (see Fig. A3 for full model)
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assess the overall diagnostic accuracy of the CART
models.24 CARTs were used to stratify patients into
low-, moderate- and high-risk groups. The post-test
probability of influenza and LR was calculated for
each of the terminal nodes in the CART tree. We used
this approach (rather than a bootstrap evaluation) be-
cause it allowed us to specify cut-offs for classification
into low-, moderate- and high-risk groups prior to
evaluation in the validation set.
Results
An analysis of patient symptoms according to influ-
enza status for the combined dataset (Table 2) shows
that patients with influenza had a much higher per-
centage of fever (63% versus 24%) and myalgia (90%
versus 63%) as well as a moderately higher percentage
of chills/sweating (85% versus 63%). However, there
is significant similarity in the prevalence of other
symptoms between cases and non-cases.
We developed three candidate CART models,
shown in Figures 1–3 (the full models are shown in
Fig. A1–A3). Model 1 (Fig. A1) initially had six splits
and seven terminal nodes but was simplified (Fig. 1)
by combining terminal nodes into a single ‘moderate-
risk’ group and by omitting ‘temperature >37.85C’
and ‘myalgia’ splits that added only 16 or 7 patients,
respectively, into high- or low-risk categories. Models
2 and 3 had only two splits and three terminal nodes.
In Models 1 and 2, temperature >37.4C (99.3 F) was
the most important predictor variable. This cut-off for
temperature was chosen by the CART algorithm as
the optimal split but may be problematic since it is at
the upper bound of the normal range. In Model 3, we
included temperature as a prespecified dichotomous
variable with a cut-off >38C (100.4 F), which is more
typical of an abnormal temperature in usual clinical
practice. Although gender and age were considered
optimal candidates for splits by the algorithm, we did
not include these splits in the model as previous multi-
variate and univariate analyses did not identify age or
gender as important variables.
Because our modelling goals were to maximize
identification of low- and high-risk patients who would
not require further diagnostic testing and to favour
simplicity, we combined the terminal nodes in Model
1 that had a probability of influenza between 10%
and 50% into a single moderate probability node.
Model 2 only had three terminal nodes, which we
designated as low, moderate and high risk. The post-
test probability and LR of flu for each node and for
the combined low-, moderate- and high-risk groups of
each model are shown in Table 3.
The most clinically useful information gained by us-
ing the prediction model is the percentage of patients
classified as low and high risk since that information
has the potential to change clinical practice. We report
separately the accuracy of Models 1, 2 and 3 for the
development, validation and combined datasets. This
percentage decreased less between derivation and val-
idation groups for Model 2 (71%–67%) than it did for
Model 1 (41%–32%) or Model 3 (57%–48%). The
key design and performance characteristics of the
TABLE 2 Symptom prevalence by influenza status
Symptom/characteristic % With
symptom
Prevalence of
symptom in influenza
positive (N = 157)
Prevalence of
symptom in influenza
negative (N = 302)
P value
Mean age (SD) 37 (14) 36 (13) 37 (15)
Temperature (C)a (SD) 37.51 (0.88) 38.03 (0.80) 37.23 (0.79)
Maleb 45 67/156 (43%) 137/301 (46%) 0.60
Fever (>37.8C)a 37 99/157 (63%) 71/302 (24%) <0.0001a
Chills 71 134/157 (85%) 190/302 (63%) <0.0001a
Myalgia 72 142/157 (90%) 193/302 (64%) <0.0001a
Duration of symptoms <2 days before
presentation
33 82/157 (52%) 69/302 (23%) <0.0001a
Fatigue 83 141/157 (90%) 240/302 (79%) 0.005a
Cough 92 150/157 (96%) 271/302 (90%) 0.03a
Rhinitis 76 128/157 (82%) 220/302 (73%) 0.04a
Headache 78 131/157 (83%) 228/302 (76%) 0.05
Sore throat 72 115/157 (73%) 217/302 (72%) 0.75
Note: The following variables that were reported in one study but not another were eliminated from the combined dataset: race, whether the visit
was the first for the given illness, days missed from work, duration of illness in days, presence of a co-morbidity, sinus pain, whether discharge was
present, colour of discharge, throat swelling, difficult swallowing, whether phlegmwas dry or scant, whether blood was present in phlegm, wheezing,
shortness of breath, painful breathing, chest pain, abdominal pain, vomiting, diarrhoea, pulse, blood pressure, respiratory rate, oxygen saturation,
toxic appearance, TM abnormality, purulent sinus drainage, sinus tenderness, tonsillar swelling, tonsillar exudates, cervical lymphadenopathy, pro-
longed expiration, decreased breath sounds, rales, rinchi, wheezes, abdominal tenderness, a clinician’s diagnosis of influenza, the results of a rapid
flu test and the week that the patient presented with symptoms.
aTemperature missing for 14 patients.
bGender missing for two patients.
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three candidate CART models are summarized in
Table 4, including the area under the receiver operat-
ing characteristic curve (AUROCC), LR’s and per-
centage of patients classified into useful risk
categories for the development and validation set for
each model.
Discussion
Model 1 has a higher AUROCC than Model 2, may
be more acceptable or believable because it uses more
clinical variables and has a higher LR for the high-risk
category. Model 2, on the other hand, is simpler and
easier to use and classifies more patients below the
test threshold or above the treatment threshold than
Model 1 (67% versus 32% for the validation set).
These are the most clinically useful classifications be-
cause they help a physician rule out or rule in influ-
enza. Model 3 has a slightly higher AUROCC than
Model 2 but classifies only 49% of validation set
patients into high- or low-risk categories. An advan-
tage of Model 3, however, is that it utilizes a tempera-
ture cut-off for fever that may be more acceptable to
physicians.
While on balance we feel that Model 2 provides the
most clinically useful model, all the models are reason-
able options depending on patient and physician prefer-
ences. Models 2 and 3 in particular could be easily
memorized. For example, during flu season, patients
with fever and an onset of symptoms <48 hours should
be empirically treated (unless there is some other obvi-
ous aetiology for their fever such as exudative pharyn-
gitis, otitis media or sinus pain and tenderness). Those
without fever but with chills or sweats should be tested
for influenza, while those without either symptom are
unlikely to have influenza. Note that this simplified
model is only an aid to clinician judgement; it is impor-
tant to remain vigilant for pneumonia and other un-
common but serious causes of similar symptoms. While
these models were accurate in our population, they
should be further validated in an independent popula-
tion that also assesses the impact on cost, test ordering,
prescribing and clinical outcomes.
CART has several advantages as a tool for develop-
ing clinical decision rules. While traditional statistical
techniques require the postulation of a model, CART
does not. When complex interactions and patterns exist
in data, they can be difficult or virtually impossible to
model.22 Furthermore, multivariate models are com-
plex, and even point scores may generate non-intuitive
results (for example when different combinations of
two or three variables give different results). A decision
tree, on the other hand, is easily understood by both
patients and physicians.
FIGURE 1 Simplified CART for Model 1 (see Fig. A1 for full
model)
FIGURE 2 CART for Model 2 (see Fig. A2 for full model)
FIGURE 3 CART for Model 3 (see Fig. A3 for full model)
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A strength of the current study is that it is one of
the first to use separate derivation and validation sub-
groups to develop and evaluate a clinical decision tool
for influenza.13 In addition, the models can be easily
memorized for use at the point of care, even without
a computer, and successfully classify a clinically mean-
ingful percentage of patients into low- or high-risk
groups that do not require further evaluation. A limi-
tation of the current study is the use of the same popu-
lation for derivation and validation, known as a ‘split
sample’ approach. The next step in our programme of
research is to prospectively validate these CART
models in a completely different population. The im-
pact of use of this and other clinical scores on the
rates of ordering office-based diagnostic tests, on pre-
scriptions for anti-influenza drugs, on cost and on clini-
cal outcomes requires further study, as demonstration
of accuracy alone is not sufficient.
Ultimately, a clinical rule or decision tree for influ-
enza should be linked to prevalence data such as that
reported regularly by the Center for Disease Control
and Prevention25 or that reported by Euroflu,26
a World Health Organization surveillance network for
European regions. A clinical rule should also be evalu-
ated in populations with different prevalences of
disease (for example, outside of flu season or during
the shoulder of flu season). The same clinical decision
rule may give different recommendations depending
on the underlying pretest probability. For example,
during shoulder season before and after the peak of
influenza, a high-risk patient may have a post-test
probability <50% and require diagnostic testing to
confirm the diagnosis. On the other hand, during peak
influenza season, they would be candidates for empiric
therapy. Thus, use of prevalence data integrated with
a clinical rule will help a clinician make the best use
of the history, physical examination and optionally di-
agnostic testing and will help them make the best deci-
sion about use of diagnostic tests and antiviral therapy.
A limitation of our study is the merging of two dis-
tinct datasets gathered from separate studies. Al-
though we believe that this decision increased the
generalizability of our model, differences in preva-
lence could reflect differences in selection criteria
between the two studies. Overfitting the CART model
to our dataset is another possible limitation, although
pruning the tree reduces that possibility. Our criterion
for assessing the benefit of an additional split was
based on percentage of patients correctly classified. Id-
iosyncrasies in our own data may have been built into
TABLE 3 Classification accuracy of the CART risk models in the derivation, validation and full datasets
Derivation group Validation group All patients
Flu/total (%) LR % In group Flu/total (%) LR % In group Flu/total (%) LR % In group
Model 1
High risk 47/60 (78) 7.2 19 14/17 (82) 7.8 13 61/77 (79) 7.1 17
Moderate risk 56/191 (29) 0.83 59 34/92 (37) 0.98 68 89/274 (32) 0.89 62
Low risk 4/71 (5.6) 0.12 22 2/25 (8) 0.15 19 6/94 (6) 0.13 21
Model 2
High risk 86/157 (55) 2.4 49 40/65 (62) 2.7 48 126/217 (58) 2.6 49
Moderate risk 17/94 (18) 0.44 29 8/44 (18) 0.37 33 24/134 (18) 0.40 30
Low risk 4/71 (6) 0.12 22 2/25 (8) 0.15 19 6/94 (6) 0.13 21
Model 3
High risk 64/102 (63) 3.4 32 25/36 (70) 3.9 26 89/139 (64) 3.4 30
Moderate risk 37/140 (26) 0.72 43 24/71 (34) 0.89 52 61/211 (29) 0.78 46
Low risk 6/80 (7.5) 0.16 25 1/30 (3) 0.06 22 7/109 (6) 0.13 24
Note: 11 cases in the derivation set and 3 in the validation set had missing temperature or gender data. Random values were used for these variables
in these cases during development and validation of the CART model.
TABLE 4 Characteristics of the three candidate CART models for predicting the likelihood of influenza
Model 1 Model 2 Model 3
Number of nodes 8 6 6
Number of terminal nodes 3 3 3
AUROCC (derivation/validation) 0.82/0.80 0.75/0.76 0.76/0.77
Percentage of patients classified as low or high
risk (derivation/validation)
41%/32% 71%/67% 57%/48%
Likelihood ratio for influenza in high-risk group
(derivation/validation)
7.2/7.8 2.4/2.7 3.4/3.9
Likelihood ratio for influenza in low-risk group
(derivation/validation)
0.12/0.15 0.12/0.15 0.16/0.06
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the model and may not validate as well in an indepen-
dent population. The test and treatment thresholds
that we used were based on a small unrepresentative
survey of primary care physicians: further work is
needed to refine these estimates.
In conclusion, we consider this to be an internal val-
idation study since the validation group was randomly
drawn from the same population as the derivation
group. Further validation in a completely independent
population, in different flu seasons and at different
times within the flu season when the prevalence
is <34% is needed. We would also like to explore
use of this model by patients, as part of a guide to
self-care that is integrated with prevalence data and
treatment recommendations.
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A strength of the current study is that it is one of
the first to use separate derivation and validation sub-
groups to develop and evaluate a clinical decision tool
for influenza.13 In addition, the models can be easily
memorized for use at the point of care, even without
a computer, and successfully classify a clinically mean-
ingful percentage of patients into low- or high-risk
groups that do not require further evaluation. A limi-
tation of the current study is the use of the same popu-
lation for derivation and validation, known as a ‘split
sample’ approach. The next step in our programme of
research is to prospectively validate these CART
models in a completely different population. The im-
pact of use of this and other clinical scores on the
rates of ordering office-based diagnostic tests, on pre-
scriptions for anti-influenza drugs, on cost and on clini-
cal outcomes requires further study, as demonstration
of accuracy alone is not sufficient.
Ultimately, a clinical rule or decision tree for influ-
enza should be linked to prevalence data such as that
reported regularly by the Center for Disease Control
and Prevention25 or that reported by Euroflu,26
a World Health Organization surveillance network for
European regions. A clinical rule should also be evalu-
ated in populations with different prevalences of
disease (for example, outside of flu season or during
the shoulder of flu season). The same clinical decision
rule may give different recommendations depending
on the underlying pretest probability. For example,
during shoulder season before and after the peak of
influenza, a high-risk patient may have a post-test
probability <50% and require diagnostic testing to
confirm the diagnosis. On the other hand, during peak
influenza season, they would be candidates for empiric
therapy. Thus, use of prevalence data integrated with
a clinical rule will help a clinician make the best use
of the history, physical examination and optionally di-
agnostic testing and will help them make the best deci-
sion about use of diagnostic tests and antiviral therapy.
A limitation of our study is the merging of two dis-
tinct datasets gathered from separate studies. Al-
though we believe that this decision increased the
generalizability of our model, differences in preva-
lence could reflect differences in selection criteria
between the two studies. Overfitting the CART model
to our dataset is another possible limitation, although
pruning the tree reduces that possibility. Our criterion
for assessing the benefit of an additional split was
based on percentage of patients correctly classified. Id-
iosyncrasies in our own data may have been built into
TABLE 3 Classification accuracy of the CART risk models in the derivation, validation and full datasets
Derivation group Validation group All patients
Flu/total (%) LR % In group Flu/total (%) LR % In group Flu/total (%) LR % In group
Model 1
High risk 47/60 (78) 7.2 19 14/17 (82) 7.8 13 61/77 (79) 7.1 17
Moderate risk 56/191 (29) 0.83 59 34/92 (37) 0.98 68 89/274 (32) 0.89 62
Low risk 4/71 (5.6) 0.12 22 2/25 (8) 0.15 19 6/94 (6) 0.13 21
Model 2
High risk 86/157 (55) 2.4 49 40/65 (62) 2.7 48 126/217 (58) 2.6 49
Moderate risk 17/94 (18) 0.44 29 8/44 (18) 0.37 33 24/134 (18) 0.40 30
Low risk 4/71 (6) 0.12 22 2/25 (8) 0.15 19 6/94 (6) 0.13 21
Model 3
High risk 64/102 (63) 3.4 32 25/36 (70) 3.9 26 89/139 (64) 3.4 30
Moderate risk 37/140 (26) 0.72 43 24/71 (34) 0.89 52 61/211 (29) 0.78 46
Low risk 6/80 (7.5) 0.16 25 1/30 (3) 0.06 22 7/109 (6) 0.13 24
Note: 11 cases in the derivation set and 3 in the validation set had missing temperature or gender data. Random values were used for these variables
in these cases during development and validation of the CART model.
TABLE 4 Characteristics of the three candidate CART models for predicting the likelihood of influenza
Model 1 Model 2 Model 3
Number of nodes 8 6 6
Number of terminal nodes 3 3 3
AUROCC (derivation/validation) 0.82/0.80 0.75/0.76 0.76/0.77
Percentage of patients classified as low or high
risk (derivation/validation)
41%/32% 71%/67% 57%/48%
Likelihood ratio for influenza in high-risk group
(derivation/validation)
7.2/7.8 2.4/2.7 3.4/3.9
Likelihood ratio for influenza in low-risk group
(derivation/validation)
0.12/0.15 0.12/0.15 0.16/0.06
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the model and may not validate as well in an indepen-
dent population. The test and treatment thresholds
that we used were based on a small unrepresentative
survey of primary care physicians: further work is
needed to refine these estimates.
In conclusion, we consider this to be an internal val-
idation study since the validation group was randomly
drawn from the same population as the derivation
group. Further validation in a completely independent
population, in different flu seasons and at different
times within the flu season when the prevalence
is <34% is needed. We would also like to explore
use of this model by patients, as part of a guide to
self-care that is integrated with prevalence data and
treatment recommendations.
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